Santhera Pharmaceuticals Holding AG

SWX:SANN Stock Report

Market Cap: CHF 126.6m

Santhera Pharmaceuticals Holding Future Growth

Future criteria checks 6/6

Santhera Pharmaceuticals Holding is forecast to grow earnings and revenue by 35.4% and 26.8% per annum respectively. EPS is expected to grow by 31.4% per annum. Return on equity is forecast to be 48.6% in 3 years.

Key information

35.4%

Earnings growth rate

31.4%

EPS growth rate

Biotechs earnings growth42.1%
Revenue growth rate26.8%
Future return on equity48.6%
Analyst coverage

Low

Last updated20 Dec 2024

Recent future growth updates

Recent updates

Santhera Pharmaceuticals Holding AG (VTX:SANN) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Dec 21
Santhera Pharmaceuticals Holding AG (VTX:SANN) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Is Santhera Pharmaceuticals Holding (VTX:SANN) Using Too Much Debt?

Dec 12
Is Santhera Pharmaceuticals Holding (VTX:SANN) Using Too Much Debt?

The Market Doesn't Like What It Sees From Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Yet

Jun 26
The Market Doesn't Like What It Sees From Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Yet

Earnings and Revenue Growth Forecasts

SWX:SANN - Analysts future estimates and past financials data (CHF Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261355361611
12/31/202548-10-6-62
12/31/202424-35-32-322
6/30/2024114632447N/A
3/31/2024109592447N/A
12/31/2023103552447N/A
9/30/202354-5-77N/A
6/30/20235-65-37-33N/A
3/31/20236-68-35-32N/A
12/31/20227-71-34-30N/A
9/30/20224-68-32-30N/A
6/30/20220-65-31-31N/A
3/31/2022-1-60-34-34N/A
12/31/2021-2-56-37-37N/A
9/30/20215-56-40-40N/A
6/30/202112-56-42-42N/A
3/31/202113-62-43-43N/A
12/31/202015-68-44-44N/A
9/30/202040-46-20-20N/A
6/30/202065-2433N/A
3/31/202070-2133N/A
12/31/201975-1923N/A
9/30/201955-37-34-14N/A
6/30/201934-54-56-36N/A
3/31/201933-54-58-37N/A
12/31/201832-54-60-38N/A
9/30/201830-58-43-41N/A
6/30/201828-56-45-42N/A
3/31/201826-54N/A-41N/A
12/31/201723-52N/A-40N/A
9/30/201722-42N/A-39N/A
6/30/201723-40N/A-33N/A
3/31/201721-38N/A-30N/A
12/31/201619-35N/A-27N/A
9/30/201615-21N/A-28N/A
6/30/201610-6N/A-29N/A
3/31/201670N/A-25N/A
12/31/201546N/A-22N/A
9/30/20154-3N/A-17N/A
6/30/20153-11N/A-11N/A
3/31/20153-10N/A-8N/A
12/31/20143-8N/A-6N/A
9/30/20142-7N/A-6N/A
6/30/20141-6N/A-5N/A
3/31/20141-6N/A-6N/A
12/31/20131-6N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SANN's forecast earnings growth (35.4% per year) is above the savings rate (0.3%).

Earnings vs Market: SANN's earnings (35.4% per year) are forecast to grow faster than the Swiss market (11.6% per year).

High Growth Earnings: SANN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SANN's revenue (26.8% per year) is forecast to grow faster than the Swiss market (4.2% per year).

High Growth Revenue: SANN's revenue (26.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SANN's Return on Equity is forecast to be very high in 3 years time (48.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Santhera Pharmaceuticals Holding AG is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maurizio BernasconiBank am Bellevue
Silvia SchanzBank Vontobel AG
Barbora BlahaCredit Suisse